Septerna
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
250 E Grand Ave, South San Francisco, Ca...Phone Number
(650) 338-3533Website
www.septerna.comRevenue
$46 MillionStock Symbol
SEPNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Septerna
Based in South San Francisco, CA, Septerna is a clinical-stage biotechnology company focused on developing new therapies targeting GPCRs. Using its proprietary Native Complex Platform, the company is advancing a pipeline of oral small-molecule drug candidates in areas such as endocrinology, immunology, inflammation, and metabolic diseases, both independently and with partners.Explore more
Septerna Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Septerna your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Septerna recently announced quarterly report
Website visits: Recent activity has been detected on your website
Septerna, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Septerna launches new products
Congratulate Masked Content for being promoted to Masked Content at Septerna
Check out if Septerna is spiking on competitors!
Funding: Get notified immidiatlly once Septerna has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Septerna had a recent Job posting/layoffs
Check if Septerna has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Septerna
Find 3 more new buyers
Compare Similar Companies to Septerna
Compare insights from companies similar to Septerna, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Septerna is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Septerna is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Septerna.
Septerna financials insights
Gather financial insights about Septerna, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$100M
2023
Series B
$150M
2024
Stock Offering
$288M
Septerna Tech Stack
A closer look at the technologies used by Septerna
Most Recent Scoops
Open Position
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Open Position
Open Position
Septerna News & Media
Septerna to Present at Bank of America Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026, at 5:00 p.m. PT in Las Vegas.Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy VolunteersSepterna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Septerna
Sign Up For FreeTo access detailed company insights
Based in South San Francisco, CA, Septerna is a clinical-stage biotechnology company focused on developing new therapies targeting GPCRs. Using its proprietary Native Complex Platform, the company is advancing a pipeline of oral small-molecule drug candidates in areas such as endocrinology, immunology, inflammation, and metabolic diseases, both ind... Read More
